Maze Therapeutics

latest press releases

latest media coverage

The Endpoints 11: The biotech startups making the biggest bets with the most exciting science in 2023
Biotech Startup Maze Therapeutics Strikes $750 Million Deal With Sanofi
Sanofi bets $750M to enter glycogen-lined Maze deal with lead asset waiting in the middle
Biotech Startup Maze Therapeutics Strikes $750 Million Deal With Sanofi
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
Sanofi’s next chapter in Pompe: $150M for Maze pact as the biotech gears up in CKD
Sanofi stock rises on licensing deal with Maze for potential Pompe disease drug
Early clinical data drove Sanofi’s decision to license Maze’s oral Pompe therapy
Sanofi pumps up its Pompe portfolio with Maze deal
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug
Updated: Maze reveals positive first look at PhI Pompe disease candidate
LifeSci 2nd Annual Genetic Medicines Symposium 2022
Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions
Maze Allies With BridgeBio and Alloy to Create 2 Biotechs
Endpoints News: Maze Therapeutics Spins Out Two New Companies with Alloy and BridgeBio
Top Life Sciences Startups to Watch in 2020
Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million
Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
MIT Technology Review: The secret to a new drug could be hiding in your genes

want to get a hold of a representative?

Jillian Connell
Maze Therapeutics

media inquires

Katie Engleman